GlassScriptPhysician profile
Natalie Cobb
NPI 1174160089
$4,986.41
in general payments reported to CMS, 2019-2025
36 companies · $1,277 in 2025
The $1,277 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $724 · 2023: $1,435 · 2024: $1,551 · 2025: $1,277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,262.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,262.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,038.38 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $778.68 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $702.02 | 2022-2025 | |
| Lilly USA, LLC | $495.82 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Eisai INC. | $154.32 | 2025 | |
| Idorsia Pharmaceuticals US INC | $149.54 | 2023 | Quviviq |
| Scynexis, INC. | $140.16 | 2022 | |
| Bioventus LLC | $136.38 | 2022 | |
| Novo Nordisk INC | $115.81 | 2023-2025 | Wegovy, Saxenda |
| Corium, LLC | $94.02 | 2023-2024 | Azstarys |
| Alexion Pharmaceuticals, INC. | $91.12 | 2024 | |
| Dexcom, INC. | $87.67 | 2022-2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $85.31 | 2022-2025 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $84.15 | 2023-2024 | Spravato |
| Amgen INC. | $75.57 | 2022-2025 | Otezla, Repatha, Otezla |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalie Cobb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.